Amarin Corporation plc (AMRN) stock news
The latest Amarin Corporation plc news and press releases. 0 news stories in the last 24 hours. AMRN stock report · Market news
Latest news
- Amarin: 3 Key Takeaways for Long-Term Investors The Motley Fool, Nov 11, 10:15 PM UTC
Amarin reported its first profitable quarter in two years during Q3. European in-market demand for VAZKEPA grew 68% year over year. - Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark Zacks Investment Research, Oct 29, 5:36 PM UTC
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase. - Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript Seeking Alpha, Oct 29, 1:30 AM UTC
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript - What Amarin (AMRN) Said on Its Q3 Earnings Call MarketBeat, Oct 28, 2:08 PM UTC
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offse... - Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) Defense World, Sep 30, 6:58 AM UTC
Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the streng... - Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN) Defense World, Sep 19, 7:57 AM UTC
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strengt... - Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research, Sep 9, 8:56 PM UTC
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Press releases
- Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026 GlobeNewsWire, Nov 9, 1:00 PM UTC
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical d... - Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income GlobeNewsWire, Oct 28, 11:00 AM UTC
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial result... - Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) GlobeNewsWire, Oct 25, 12:11 PM UTC
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved W... - Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 GlobeNewsWire, Oct 21, 12:00 PM UTC
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report thir... - Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 GlobeNewsWire, Aug 31, 12:15 PM UTC
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) - New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients GlobeNewsWire, Aug 28, 12:15 PM UTC
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc ... - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 GlobeNewsWire, Aug 24, 12:15 PM UTC
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presenta...
Headlines link to their publishers. Research data, not investment advice.